1. Research Framework
1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation
2. Research Methodology
2.1. Qualitative Research
2.1.1. Primary and Secondary Sources
2.2. Quantitative Research
2.2.1. Primary and Secondary Sources
2.3. Breakdown of Primary Research Respondents
2.3.1. Secondary Research
2.3.2. Primary Research
2.4. Breakdown of Primary Research Respondents, By Industry Participants
2.5. Key Questionnaire asked during Primary Interviews
2.6. Key Primary Responses
2.7. Market Size Estimation
2.8. Assumption for the Study
2.9. Market Breakdown & Data Triangulation
3. Executive Summary
4. Global Antibody Drug Conjugate Market Industry Insights
4.1. Industry Value Chain Analysis
4.2. DROC Analysis
4.2.1. Growth Drivers
4.2.2. Restraints
4.2.3. Opportunity
4.2.4. Challenges
4.3. Regulatory Framework
4.4. Antibody Drug Conjugates Mechanism of Action
4.5. Porters Five Forces Analysis
5. Global Antibody Drug Conjugate Market Overview
5.1. Market Estimates & Forecast by Value, 2017-2027
5.1.1. By Value (USD Million)
5.2. Market Share & Forecast
5.2.1. By Type
5.2.1.1. Cleavable Linker
5.2.1.2. Non-cleavable Linker
5.2.2. By Application
5.2.2.1. Blood Cancer
5.2.2.1.1. Leukemia
5.2.2.1.2. Multiple Myeloma
5.2.2.1.3. Lymphoma
5.2.2.2. Breast Cancer
5.2.2.3. Urothelial Cancer & Bladder Cancer
5.2.2.4. Others
5.2.3. By End Users
5.2.3.1. Research Institutes
5.2.3.2. Biotechnology Companies
5.2.3.3. Hospitals
5.2.3.4. Clinics
5.2.4. By Region
5.2.4.1. North America
5.2.4.2. Europe
5.2.4.3. The Asia-Pacific (APAC)
5.2.4.4. Latin America (LATAM)
5.2.4.5. The Middle-East & Africa (MEA)
6. North America Antibody Drug Conjugate Market Overview
6.1. Market Size and Forecast
6.1.1. By Value (USD Million), 2017-2027
6.2. Market Share and Forecast
6.2.1. By Type
6.2.2. By Application
6.2.3. By End Users
6.2.4. By Country
6.2.4.1. U.S.
6.2.4.2. Canada
7. Europe Antibody Drug Conjugate Market Overview
7.1. Market Size and Forecast
7.1.1. By Value (USD Million), 2017-2027
7.2. Market Share and Forecast
7.2.1. By Type
7.2.2. By Application
7.2.3. By End Users
7.2.4. By Country
7.2.4.1. Germany
7.2.4.2. U.K.
7.2.4.3. France
7.2.4.4. Italy
7.2.4.5. Rest of Europe
8. Asia Pacific Antibody Drug Conjugate Market Overview
8.1. Market Size and Forecast
8.1.1. By Value (USD Million), 2017-2027
8.2. Market Share and Forecast
8.2.1. By Type
8.2.2. By Application
8.2.3. By End Users
8.2.4. By Country
8.2.4.1. China
8.2.4.2. India
8.2.4.3. Japan
8.2.4.4. South Korea
8.2.4.5. Rest of Asia-Pacific
9. Latin America Antibody Drug Conjugate Market Overview
9.1. Market Size and Forecast
9.1.1. By Value (USD Million), 2017-2027
9.2. Market Share and Forecast
9.2.1. By Type
9.2.2. By Application
9.2.3. By End Users
9.2.4. By Country
9.2.4.1. Argentina
9.2.4.2. Brazil
9.2.4.3. Rest of LATAM
10. Middle East & Africa Antibody Drug Conjugate Market Overview
10.1. Market Size and Forecast
10.1.1. By Value (USD Million), 2017-2027
10.2. Market Share and Forecast
10.2.1. By Type
10.2.2. By Application
10.2.3. By End Users
10.2.4. By Country
10.2.4.1. Saudi Arabia
10.2.4.2. UAE
10.2.4.3. South Africa
10.2.4.4. Rest of Middle East & Africa
11. List of Antibody Drug Conjugates Patent Landscape
12. Antibody Drug Conjugates Pipeline Analysis
13. Competitive Landscape
13.1.1. List of Key Producers and Their Offerings
13.1.2. Market Share / Ranking Analysis (2020)
13.1.3. Competitive Benchmarking, By Operating Parameters
13.1.4. Antibody-Drug Conjugate Licensing and Merger and Acquisition (M&A) Deals
14. Impact of COVID-19 Across Industry
15. Company Profiles (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *
15.1. Takeda Pharmaceutical Company Ltd.
15.2. F. Hoffmann-La Roche AG
15.3. Pfizer, Inc.
15.4. AstraZeneca
15.5. Gilead Sciences, Inc.
15.6. Astellas Pharma
15.7. Seagen, Inc.
15.8. Daiichi Sankyo Company Ltd.
15.9. GlaxoSmithKline Plc
15.10. Genentech Inc.
16. Key Strategic Recommendations
* Financial information in case of non-listed companies will be provided as per availability
**The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable